ALK+ advanced NSCLC

Clinical trials for ALK+ advanced NSCLC explained in plain language.

Never miss a new study

Get alerted when new ALK+ advanced NSCLC trials appear

Sign up with your email to follow new studies for ALK+ advanced NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Lung cancer showdown: which targeted pill works better after crizotinib fails?

Disease control Completed

This phase 3 trial tested two targeted drugs, brigatinib and alectinib, in 248 people with advanced ALK-positive non-small-cell lung cancer whose cancer had worsened after taking crizotinib. Participants were randomly assigned to take either brigatinib or alectinib daily. The mai…

Matched conditions: ALK+ ADVANCED NSCLC

Phase 3 • Sponsor: Takeda • Aim: Disease control

Last updated Jun 26, 2026 16:05 UTC

ALK+ advanced NSCLC

Get alerted when new ALK+ advanced NSCLC trials appear

Lung cancer showdown: which targeted pill works better after crizotinib fails?